bs-2386R-Biotin [Conjugated Primary Antibody]
CD47/MER6 Polyclonal Antibody, Biotin Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CD47/MER6

Immunogen Range: 241-323/323


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 961

Swiss Prot: Q08722

Source: KLH conjugated synthetic peptide derived from human CD47/MER6

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.

Conjugation: Biotin

Excitation/ Emission: N/A

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)

Predicted Molecular Weight: 33


Cross Reactive Species: Mouse
Rat

Predicted Cross Reactive Species: Human
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Miedel, Emily, et al. "Disruption of thrombospondin?\2 accelerates ischemic fracture healing."Journal of Orthopaedic Research (2012).aRead more>>
  • Miedel, Emily, et al. "Disruption of thrombospondin?\2 accelerates ischemic fracture healing."Journal of Orthopaedic Research (2012))Read more>>
  • Xu, C., et al. "Proteomics Analysis of Hepatocyte Proliferation Regulated by FGF, PDGF, Insulin, Oncostatin M and Interleukin 2 Signaling Pathways during Rat Liver Regeneration." J Proteomics Computational Biol 1.1 (2014): 8.Read more>>
  • Kaiyuan Wanget al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition. Biomaterials. 2020 Oct;257:120224.Read more>>
  • Xuanbo Zhang. et al. Erythrocyte membrane-camouflaged carrier-free nanoassembly of FRET photosensitizer pairs with high therapeutic efficiency and high security for programmed cancer synergistic phototherapy. Bioact Mater. 2021 Aug;6:2291Read more>>
  • Ying Long. et al. A hybrid membrane coating nanodrug system against gastric cancer via VEGFR2/STAT3 signaling pathway. 2021 Apr 07Read more>>
  • Meng Lin. et al. CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. Nano Today. 2022 Feb;42:101359Read more>>
  • Zhongjie Tang. et al. Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting Strategy. Advanced Science. 2023 Jan;:2206912Read more>>
  • Chunliang Zhang. et al. Red blood cell membrane-functionalized Nanofibrous tubes for small-diameter vascular grafts. BIOMATERIALS. 2023 Apr;:122124Read more>>
  • Qing Dong. et al. Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy. INT J BIOL MACROMOL. 2023 Apr;:124342Read more>>
  • Chang Xiao. et al. Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy via excessive autophagy. ACTA PHARM SIN B. 2023 MayRead more>>
VALIDATION IMAGES